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INTRODUCTION
Obesity is a well-known determinant contributing to a
g reater risk of inferior health, disease, and pre m a t u re death
[1]. Health maintenance or treatment, whether re q u i r i n g
medical or surgical intervention, proves more difficult in the
obese patient population. Obese renal transplant patients
have been found to be at significantly increased risk of mor-
t a l i t y, postoperative complications, intensive care unit
admissions, reintubations, new onset diabetes, and decre a s e d
1-year graft survival [2,3]. Studies have shown that bone
m a rrow transplantation outcome can be affected by numer-
ous risk factors that can be identified before, during, and
after transplantation [4–6]. Such factors as advanced disease,
type of conditioning regimen, older age, and previous tre a t-
ment are considered to be risk factors by some experts [7–10]. 
Both obesity and undernourishment have been consid-
ered risk factors for complications and increased nonrelapse
m o rtality (NRM) in bone marrow transplant patients, and
significantly worse survival has been demonstrated in
s e v e rely underweight bone marrow transplant patients
[11–13]. Chemotherapy dose modifications are re c o m m e n ded
by some for obese patients [14,15] but not by others [16,17].
In underweight patients, actual body weight (ABW) at the
time of admission is used for determining chemotherapy
dosing. In overweight patients, chemotherapy dosing is
adjusted down based on the relationship of ABW and ideal
body weight (IBW). This adjustment i s intended to
e l i m inate potential “overdosing,” leading to increased dru g
toxicity and complications such as organ failure or skin
b reakdown. The current study explored the relationship of
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ABSTRACT
We perf o rmed a re t rospective analysis of 473 consecutive adult patients undergoing autologous bone marrow trans-
plantation for hematologic malignancies between 1988 and 1995. The analysis examined whether significant devia-
tion from ideal body mass index is associated with a decrease in event-free survival (EFS), an increase in nonre l a p s e
m o rtality (NRM) including late toxicities and second malignancies, or relapse. Chemotherapy dosing in under-
weight and overweight patients is administered based on the relationship of admission body weight (ABW) to ideal
body weight (IBW). Doses were adjusted for obesity; however, the adjustment did not obviate increased risk for
NRM. Patients were categorized into five groups according to the relationship of ABW to age-adjusted body mass
index (aBMI) as a percent of actual BMI, as follows: group I, 70–79%; group II, 80–99%; group III, 100–119%;
g roup IV, 120–139%; and group V, 140–199% aBMI. When body weight was expressed as percent BMI adjusted for
age, there was a significantly increased risk for NRM in groups I and IV (p = 0.03 and 0.02, respectively). A tre n d
t o w a rd greater NRM in group V (p = 0.10) was also noted. Multivariate analysis confirmed that the risk of NRM for
e x t remely underweight and overweight patients is almost three times that of patients close to ideal body weight.
Age-adjusted BMI was an independent predictive factor for NRM but not associated with increased relapse. We
d e t e rmined that dose adjustment could be safely used without significant increase of relapse. In patients with
s i g n i ficant deviation of BMI from aBMI, dose adjustment and possible weight normalization should be considered. 
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o b e s ity and a specific chemotherapy dose-adjustment algo-
rithm with risk of mortality and relapse in patients undergo-
ing autologous bone marrow transplantation.
METHODS
We reviewed the re c o rds of 473 consecutive patients who
u n d e rwent autologous bone marrow transplantation at Stan-
f o rd University Hospital Adult Unit between January 1988
and Febru a ry 1995. Diseases included non-Hodgkin’s lym-
phoma (n5238), Hodgkin’s disease (n5119), multiple myelo-
ma (n554), and acute myelogenous leukemia (n562). Admis-
sion body weight was re c o rded before beginning the pre p a r a-
t o ry regimen. Ideal body weight was calculated using Devine’s
f o rmulas [18]: 50 kg 1 [2.3 kg 3 (height in inches – 60)] for
men; 45.5 kg 1 [2.3 kg 3 (height in inches – 60)] for women.
Patients were treated with one of seven pre p a r a t o ry re g i-
mens according to age, underlying disease, and prior therapy,
as illustrated in Fig. 1. Chemotherapy dosing was computed
based on ABW unless ABW was .15 kg above IBW, in
which case the dose was computed by 40% adjustment
between ABW and IBW: Adjusted body weight 5 IBW 1
0.4(ABW – IBW). These are standard established calculations
used for our autologous transplant patients. Supportive meas-
u res such as hydration, blood products, antifungal and
antibacterial prophylaxis, bro a d - s p e c t rum antibiotics, and
total parenteral nutrition were provided according to clinical
s t a n d a rd pro c e d u res. 
To examine outcome in relation to obesity and age, data
were grouped using age-adjusted body mass index (BMI) in
kg/m2. Age-adjusted BMI is a calculated BMI at which the
minimum mortality occurred at each decade of life [19]
using life insurance data published in 1980 [20]. Age-adjust-
ed BMIs for each age group are as follows: 16–18 years, 20;
19–24, 21.5; 25–34, 22.5; 35–44, 23.5; 45–54, 24.5; and
55–65, 25.5. Using the mean (100%) of age-adjusted BMI
(aBMI) [21], the cohort was grouped into five classes (I–V).
Each patient was classified with this technique into an aBMI
category as a percentage of actual BMI. Patients were classi-
fied into five groups based on ABW in relation to aBMI:
g roup I, aBMI 70–79%, n517; group II, aBMI 80–99%,
n5166; group III, aBMI 100–119%, n5186; group IV,
aBMI 120–139%, n572; group V, aBMI 140–199%, n532.
Patients were grouped by deciles of age-adjusted BMI, and
deciles of the extremes of the distribution were combined
because there were so few extremes. 
Patient data were analyzed using the SAS system [22].
Actuarial NRM, event-free survival (EFS), and relapse rate
were estimated using the method of Kaplan and Meier [23].
Actuarial NRM was estimated using death without re l a p s e
as an event and time of last live contact as a censor; EFS
using relapse or death as events and time of last live contact
as a censor; and actuarial relapse rate using relapse as an
event and time of last live contact or death without relapse
as censors.
Using group III as the re f e rence group, we compare d
groups of deviation from desirable body weight by log-rank
statistics, except the comparison of regimen-related mortali-
ty (RRM), for which Fisher’s exact test was used. Influence
of aBMI, age, sex, regimen (with vs. without fractionated
Figure 1. Preparatory regimens in 473 autologous transplant procedures
FTBI amounts in rads. ABMT, autologous bone marrow transplantation; BCNU, carmustine; BU, busulfan; CCNU, lomustine; CY, cyclophosphamide; PBPCT,
peripheral blood progenitor cell transplant; VP-16, etoposide.
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total-body irradiation [FTBI]), disease status (minimal vs.
advanced, where minimal is acute myelogenous leukemia in
first complete remission, Hodgkin’s disease in first or second
complete or partial remission or first relapse, non-Hodgkin’s
lymphoma in first or second complete remission, first or
second partial response, or chemosensitive myeloma treated
with no more than two standard chemotherapy re g i m e n s ) ,
and year of transplantation on NRM, EFS, and relapse rate
w e re examined by Cox’s pro p o rtional hazard re g re s s i o n
using a forw a rd stepwise analysis; relative risks (RRs) are
reported [24]. Covariates are displayed in Table 1.
RESULTS
Four hundred seventy-three patients received autolo-
gous grafts. Data are re p o rted with a median follow-up of
2.3 years; median follow-up of surviving patients was 3.8 years
(range 0.3–9.1). Tables 2 and 3 display the actuarial esti-
mates of 5-year EFS, relapse, and NRM, with p values rep-
resenting comparisons to group III using the log-rank
method. There was a significant increase in NRM in groups
I and IV (18 6 13, p 5 0.03, and 24 6 6%, p 5 0.02, respec-
tively) and a trend toward an increased NRM in group V
(25 6 10%, p 5 0.10). There were no statistically significant
d i ff e rences in EFS and relapse between the groups. The
p ro p o rtion of group I patients dying within 100 days of
transplant was three times that of group III (18 vs. 6%, p 5
0.10). There were no statistically significant diff e re n c e s
between RRM of group III and the other groups. Kaplan-
Meier curves for EFS, relapse, and NRM are presented in
Figures 2, 3, and 4, respectively. 
The association between aBMI and NRM found by
multivariate analysis was confirmed when allowance was
made for the other covariates. A proportional hazards multi-
variate analysis was perf o rmed for each of the endpoints
( Table 4). The overall p value for the aBMI variation was
0.03. The effect was estimated to attain an almost threefold
RR for the more extreme underweight and for the two over-
weight patient groups, relative to the risk for patients in the
ideal aBMI group.There was a significant increase in RR of
NRM in groups IV (RR 2.9, p 5 0.003) and V (RR 2.7, p 5
0.05). Respectively, there was a trend toward an increase in
RR of NRM in the extremely underweight group I (RR 2.7,
p 5 0.08).
No relation between aBMI and EFS or relapse was
noted. Advanced disease status was a predictor of higher
relapse and decreased EFS. Patients who received an FTBI-
containing preparatory regimen also had superior EFS and
lower relapse. There were no correlations for the covariates,
including transplant type. As determined by x2 test, neither
transplant type (bone marrow vs. peripheral blood) nor regi-
men (FTBI vs. no FTBI) made a diff e rence in RRM by
weight group among the 40 patients who experienced RRM
(p 5 0.191 and 0.925, respectively). 
DISCUSSION
Our results indicate an increased NRM in obese patients
u n d e rgoing autologous bone marrow transplantation, con-
firming re p o rts from other organ transplant and hospitalized
patient populations in which less favorable outcomes tended
to be related to patients classified as obese [3,25,26]. Other
studies have used diff e rent body weight groupings, and sev-
eral diff e rent definitions of obesity are used in the literature
[27–32]. Currently no published tables for IBW account for
e t h n i c i t y, age, percent body fat, or general health status.
R e cognizing these limitations, we used BMI [33,34] in our
Table 1. Patient characteristics (n=473)
Age (y)
Median 41
Range 14–65
Sex
Female 188
Male 285
Disease status
Minimal 370
Advanced 103
Regimen
Non-FTBI 266
FTBI 207
Transplant type
Peripheral blood 261
Bone marrow 212
Follow-up term (y)
Median 2.3
Range 0.02–9.08
Live patient follow-up (y)
Median 3.8
Range 0.3–9.1
Actual BMI
Median 24.7
Range 15.8–46.2
Diagnosis
Acute leukemia 62
Hodgkin’s disease 119
Multiple myeloma 54
Non-Hodgkin’s lymphoma 238
BMI, body mass index; FTBI, fractionated total body irradiation.
Table 2. Kaplan-Meier estimates of EFS, relapse rate, and NRM according to aBMI groups
Age-adjusted BMI group n 5-year EFS p 5-year relapse rate p 5-year NRM p 100-day RRM p
I (70–79%) 17 37 6 13 0.19 48 6 15 0.73 18 6 13 0.03 18 0.01 
II (80–99%) 166 40 6 4 0.09 52 6 5 0.23 15 6 3 0.22 9 0.31 
III* (100–119%) 186 47 6 4 — 45 6 4 — 13 6 3 — 6 —
IV (120–139%) 72 39 6 7 0.31 47 6 9 0.88 24 6 6 0.02 10 0.29
V (140–199%) 32 33 6 10 0.23 55 6 12 0.62 25 6 10 0.10 13 0.25 
*Reference group.
Data are percent ± SE . p values were determined by Fisher’s exact test, two-tailed.
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analysis. In this study, the patients were grouped by deciles of
age-adjusted BMI; combining deciles in the extremes of the
distribution may have underestimated the risks for the
e x t reme weight populations. 
Outcome results for obese patients may relate to the
ambiguities of chemotherapy dose adjustments. Although
obese patients have exhibited a reduced clearance with some
chemotherapeutic agents [29] and a potentially longer drug
e x p o s u re [15], no uniform clinical dosing guidelines based
on weight have been established. A recent study demon-
strated marked variability among institutions perf o rm i n g
B M Ts according to the method of dose adjustment used
[35]. Obese individuals have altered pharmacokinetics for
many medications, and obesity has generally been thought
to increase risk of operative mortality and postoperative
complications [3,26,27]. Some studies of cancer patients
have shown worse treatment outcomes in obese patients but
have also demonstrated a decreased incidence of life-threat-
ening infection [14]. Other studies have demonstrated no
s u p p o rt for empiric chemotherapy dose reductions based
on body weight [16,17]. In breast cancer patients receiving
adjuvant chemotherapy, the risk of disease re c u rrence for
obese patients was 1.33 times that of the nonobese popula-
tion [17]. However, other investigators observed that
underweight as well as overweight status is predictive of an
u n f avorable prognosis for breast cancer [36]. The Eastern
Cooperative Oncology Group (ECOG) found adverse out-
come with increasing adiposity in breast cancer patients
[37]. The North Central Oncology Group (NCOG) deter-
mined that a middle-range value of BMI correlated with a
better relapse-free survival rate than those with the high or
low ranges of BMI for patients with breast cancer [38].
Table 3. Kaplan-Meier estimates of 5-year EFS according to early or advanced disease
Early disease Advanced disease
Group n % 6 SE p No. of events n % 6 SE p No. of events 
I 14 45 6 140 .35 7 3 0 0.13 3
II 131 43 6 5 0.05 73 35 29 6 8 0.99 24 
III* 143 52 6 4 — 66 43 26 6 8 — 29
IV 59 41 6 80 .28 30 13 26 6 13 0.48 9
V 23 37 6 120 .41 12 9 22 6 14 0.46
7 
Total 370 188 103 72
*Reference group.
p values were determined by Fisher’s exact test, two-tailed.
Figure 2. Probability of event-free survival according to aBMI groups
Curve 1, group I, 70–79% aBMI; curve 2, group II, 80–99% aBMI; curve 3, group III, 100–119% aBMI; curve 4, group IV, 120–139% aBMI; curve 5,
group V, 140–199% aBMI.
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Figure 3. Probability of relapse according to aBMI groups
Curve 1, group I, 70–79% aBMI; curve 2, group II, 80–99% aBMI; curve 3, group III, 100–119% aBMI; curve 4, group IV, 120–139% aBMI; curve 5,
group V, 140–199% aBMI.
Figure 4. Probability of nonrelapse mortality according to aBMI groups
Curve 1, group I, 70–79% aBMI; curve 2, group II, 80–99% aBMI; curve 3, group III, 100–119% aBMI; curve 4, group IV, 120–139% aBMI; curve 5, group
V, 140–199% aBMI.
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Dose intensity is considered a paradigm of disease
management for patients with diagnoses such as otherw i s e
incurable lymphoma and breast cancer. Lower dose inten-
sity may be used for obese patients compared with patients
of normal weight because of the trend of using IBW for
dose adjustment and underestimating tolerance. Substan-
tial variations result in calculated dose or dose intensity
d i ff e rences. In bone marrow transplantation, chemo-
therapy doses are given at the maximum tolerated doses in
an attempt to cure disease; however, patients who fell out-
side ideal weight ranges may be at greater risk of relapse or
d rug toxicity. Overweight patients dosed at adjusted or
ideal weight may be receiving insufficient treatment and
t h e re f o re be at greater risk of relapse, and underw e i g h t
patients dosed at ideal weight may be overdosed and thus
inclined to experience increased drug toxicity.
Our results suggest that dose adjustment based on
admission body weight can safely be used without signifi-
cant increase in relapse rate. However, overweight patients
may be at an increased risk for nonrelapse mort a l i t y, and
the lower normal weight patients (aBMI 80–99%) showed
a decreased EFS (not statistically significant). In patients
with significant deviation of ABW from IBW (,80 or
.120% aBMI), dose adjustment as well as possible weight
n o rmalization should be considered and studied along with
other nutritional assessment tools for determination of
lean body mass or physical fitness. Unfort u n a t e l y, like
other risk factors identified before administering chemo-
t h e r a p y, extremes of weight may be another known and
unchangeable risk factor to consider. The use of form a l
p h a rmacokinetic studies in obese patients underg o i n g
high-dose chemotherapy is warranted. 
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